Japanese Journal of Clinical Oncology Advance Access originally published online on January 17, 2006
Japanese Journal of Clinical Oncology 2006 36(2):113-115; doi:10.1093/jjco/hyi215
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 Foundation for Promotion of Cancer Research
Case Report |
Parathyroid Hormone-related Protein-Secreting Uterine Endometrioid Adenocarcinoma
1 Department of Gynecology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, 2 Department of Pathology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, 3 National Hospital Organization, Kure Medical Center, Kure, Hiroshima, Japan
For reprints and all correspondence: Ken-ichirou Morishige, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka City 537-8511, Japan. E-mail: morisige-ke{at}mc.pref.osaka.jp
Received June 21, 2005; accepted November 14, 2005
The diagnosis of parathyroid hormone-related protein (PTHrP)-secreting metastatic uterine endometrioid cancer was made in a 32-year-old Japanese woman with humoral hypercalcemia of malignancy. The primary endometrial cancer had been removed, and the tumor was diagnosed as Grade 1 endometrioid adenocarcinoma with shallow myometrial invasion. Salvage chemotherapy (paclitaxel and calboplatin) was started from 5 months after surgery when recurrent tumors were detected in the peritoneum and liver. Despite the salvage chemotherapy, the tumor progressed and hypercalcemia became evident with elevated PTHrP whereas no bone metastasis was identified. To the best of our knowledge, this is the first reported case of hypercalcemia due to PTHrP secretion in uterine endometrioid adenocarcinoma.
Key Words: humoral hypercalcemia of malignancy endometrioid adenocarcinoma endometrial cancer parathyroid hormone-related protein